ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

EWTX Edgewise Therapeutics Inc

16.17
0.23 (1.44%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Edgewise Therapeutics Inc EWTX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.23 1.44% 16.17 10:00:00
Open Price Low Price High Price Close Price Previous Close
16.06 15.985 16.93 16.17 15.94
more quote information »

Recent News

Date Time Source Heading
23/4/202422:00BWEdgewise Receives European Medicines Agency (EMA) Orphan..
16/4/202406:05BWEdgewise Therapeutics Announces Positive Two-Year Topline..
28/3/202423:00BWEdgewise Therapeutics Announces Upcoming Podium Presentation..
27/3/202423:00BWEdgewise Therapeutics to Present at the Cantor Virtual..
06/3/202400:00BWEdgewise Therapeutics to Present at the Leerink Partners..
29/2/202400:00BWEdgewise Therapeutics to Present on EDG-5506 for the..
23/2/202400:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
23/2/202400:00EDGAR2Form 8-K - Current report
23/2/202400:00BWEdgewise Therapeutics Reports Fourth Quarter and Full Year..
15/2/202400:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202400:00BWEdgewise Receives U.S. FDA Fast Track Designation for..
10/2/202409:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202408:15EDGAR2Form 144 - Report of proposed sale of securities
20/1/202408:54EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/1/202400:44EDGAR2Form 8-K - Current report
20/1/202400:37BWEdgewise Therapeutics Announces Pricing of $240 Million..
19/1/202422:05EDGAR2Form 8-K - Current report
19/1/202422:04EDGAR2Form S-3MEF - Registration adding securities to prior Form..
19/1/202422:02EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/1/202400:39BWEdgewise Therapeutics Highlights 2023 Accomplishments and..
29/12/202308:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202308:32EDGAR2Form 144 - Report of proposed sale of securities
20/12/202300:00BWEdgewise Therapeutics to Present at the 42nd Annual J.P...
19/12/202300:00BWEdgewise Therapeutics Launches First of Its Kind Educational..
01/12/202300:56DJNEdgewise Gets FDA Orphan, Rare-Pediatric-Disease..
01/12/202300:00BWEdgewise Receives Orphan Drug and Rare Pediatric Disease..
10/11/202300:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/11/202300:00EDGAR2Form 8-K - Current report
10/11/202300:00BWEdgewise Therapeutics Reports Third Quarter 2023 Financial..
09/11/202300:00BWEdgewise Therapeutics to Present at Upcoming Investor..
01/11/202323:00BWEdgewise to Present Data on EDG-7500 at the American Heart..
26/10/202323:00BWEdgewise Therapeutics Announces Expansion of their EDG-5506..
27/9/202322:00BWEdgewise Therapeutics to Present on EDG-5506 for Becker..
26/9/202322:00BWEdgewise Therapeutics Announces Initiation of GRAND CANYON,..
14/9/202322:00BWEdgewise Therapeutics Begins Dosing First-in-Human Phase 1..
19/8/202309:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/8/202309:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:00EDGAR2Form 8-K - Current report
10/8/202322:00BWEdgewise Therapeutics Reports Second Quarter 2023 Financial..
15/7/202306:05EDGAR2Form 8-K - Current report
27/6/202306:01BWEdgewise Therapeutics Announces Positive 12-Month Topline..
06/6/202322:00BWEdgewise Therapeutics to Present at the Goldman Sachs Global..
11/5/202322:00BWEdgewise Therapeutics Reports First Quarter 2023 Financial..
02/5/202322:00BWEdgewise Therapeutics to Present at Upcoming Investor..

Your Recent History

Delayed Upgrade Clock